Advanced Cervical Cancer Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

 Breaking News
  • No posts were found

Advanced Cervical Cancer Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

January 23
17:14 2023
Advanced Cervical Cancer Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Advanced Cervical Cancer Pipeline Insight, 2023,” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Advanced Cervical Cancer pipeline landscape. It covers the pipeline drug profiles, including Advanced Cervical Cancer clinical trials and nonclinical stage products. It also covers the Advanced Cervical Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Advanced Cervical Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Advanced Cervical Cancer clinical trials studies, Advanced Cervical Cancer NDA approvals (if any), and product development activities comprising the technology, Advanced Cervical Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key Takeaways from the Advanced Cervical Cancer Pipeline Report

 

  • DelveInsight’s Advanced Cervical Cancer Pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Advanced Cervical Cancer treatment.

 

  • The leading Advanced Cervical Cancer companies such as Akeso Biopharma, Hookipa Biotech GmbH, Biocad, Shanghai Henlius Biotech, Genexine, Inc., GlaxoSmithKline, EMD Serono, Zeria Pharmaceutical, Agenus Inc., Corregene Biotechnology Co., Ltd, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nykode Therapeutics, Instil Bio, Fujifilm Pharmaceuticals U.S.A., Inc., Nurix Therapeutics, Inc., Bristol-Myers Squibb, NETRIS Pharma, Suzhou BlueHorse Therapeutics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Xencor, Inc., Adlai Nortye Biopharma Co., Ltd., SOTIO, Astex Pharmaceuticals, Inc., Rubius Therapeutics, Seagen Inc., Kymab Limited, Incyte Corporation, Ocellaris Pharma, Inc., NGM Biopharmaceuticals, Inc., Nurix Therapeutics, Inc., Andes Biotechnologies, Arcus Biosciences, Inc., AstraZeneca, OncoC4, Inc., Turnstone Biologics, Corp., Nanobiotix, HiFiBiO Therapeutics, Corvus Pharmaceuticals, Inc., NGM Biopharmaceuticals, Inc., Prelude Therapeutics, Medicenna Therapeutics, Inc., Tarveda Therapeutics, Synthekine, RAPT Therapeutics, Inc., Shattuck Labs, Inc., BioAtla, Inc., Quadriga Biosciences, Inc., Klus Pharma Inc., Exelixis, Jiangsu HengRui Medicine Co., Ltd., Genor Biopharma Co., Ltd., Genentech, Qilu Pharmaceutical Co., Ltd., Lee’s Pharmaceutical Limited, Guangzhou Gloria Biosciences Co., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd., ISA Pharmaceuticals B.V., Agenus Inc., Cellid Co., Ltd., Advenchen Laboratories, LLC, TCRCure Biopharma Ltd., Iovance Biotherapeutics, Inc., MacroGenics, Transgene, Nanobiotix, Antengene Corporation, and others are developing novel drug candidates to improve the Advanced Cervical Cancer treatment landscape.

 

  • Promising Advanced Cervical Cancer pipeline therapies in various stages of development include AK104, HB-201, BCD-100, HLX10, GX-188E, TSR-042, M7824, Z-100, CRTE7A2-01, TQ-B3525, VB10.16, Bintrafusp alfa, ITIL-168, FF-10850, De-TIL-0255, BMS-986340, NP137, LM 103, SG001, AK112, XmAb20717, SO-C101, AN0025, ASTX660, RTX-321, SGN-ALPV, KY1044, SGN-B6A, INCB099318, OC-001, NGM707, NX-1607, Andes-1537, AB308, AZD8701, ONC-392, TBio-6517, NBTXR3, SEA-TGT, HFB200301,  CPI-006, NGM438, PRT1419, MDNA11, PEN-866, tucatinib, STK-012, FLX475, SL-279252, BA3071, QBS10072S, A166, XB002, TQB2450, SHR-1210, GB226, Atezolizumab, QL1604, ZKAB001, GLS-010, SHR-1701, ISA101b, SG001, AGEN1884, BVAC-C, AL3818, TC-E202 cells, LN-145, NP137, SO-C101, XmAb20717, MGD013, TG4001, QBS10072S, NBTXR3, ATG-008, and others.

 

  • Advanced Cervical Cancer Pipeline Segmentation: Phases, Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

 

To explore more information on the latest breakthroughs in the Advanced Cervical Cancer Pipeline treatment landscape of the report, click here @ Advanced Cervical Cancer Pipeline Outlook

 

Recent Developmental Activities in the Advanced Cervical Cancer Treatment Landscape

 

  • In June 2022, Antengene Corporation Limited announced that an abstract titled “A phase I/II study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in patients with advanced solid tumors (TORCH-2)” will be presented as a poster during the 2022 American Society of Clinical Oncology (ASCO 2022), taking place from June 3rd to 7th in Chicago, Illinois via in-person or virtual attendance.
  • In May 2022, Nykode Therapeutics AS announced positive interim results from its Phase 2 VB C-02 trial of VB10.16, its wholly-owned therapeutic cancer vaccine, in combination with the PD-L1 inhibitor atezolizumab in patients with HPV16-positive advanced cervical cancer. Interim results from 39 patients with a median follow-up of 6 months show an ORR of 21%—including two patients who achieved a complete response and six who achieved a partial response—and a very high disease control rate of 64%. The trial enrolled a heavily pre-treated patient population, with more than two-thirds of the patients having received at least two previous systemic lines of treatment.
  • In May 2022, NGM Biopharmaceuticals, Inc. (NGM Bio) announced it had initiated a Phase 1/1b clinical study of NGM438 for the treatment of patients with advanced solid tumors. The trial will enroll up to approximately 80 adult patients with multiple tumor types, including pancreatic cancer, breast cancer, mesothelioma, gastric cancer, non-small cell lung cancer (NSCLC), cervical and endocervical cancer, biliary duct cancer (cholangiocarcinoma), squamous cell carcinoma of the head and neck (SCCHN), urothelial bladder cancer, colorectal cancer (CRC), esophageal cancer, ovarian cancer, renal cell carcinoma (RCC), prostate cancer and melanoma (skin cutaneous).
  • In April 2022, Nurix Therapeutics, Inc. announced that the first patient had been dosed in its Phase 1 clinical trial of DeTIL-0255, a drug-enhanced tumor-infiltrating lymphocyte therapy and the lead candidate in its cellular therapy portfolio. The trial is designed to evaluate the safety and efficacy of DeTIL-0255 in patients with advanced gynecological malignancies, including ovarian cancer, cervical cancer, and endometrial cancer.
  • In November 2021, TCRCure announced that they had received Investigational New Drug (IND) approval from the CENTER FOR DRUG EVALUATION, NMPA (the “CDE”)for the Phase 1/2 clinical study of Modified autologous T cells for targeting HPV and delivery of anti-PD-1 in the treatment of HPV-positive recurrence and metastasis cervical cancer.

 

Advanced Cervical Cancer Overview

Advanced cervical cancer means the cancer has spread from the cervix to another area of the body such as the lungs. Sometimes cancer is advanced when it is first diagnosed. Unfortunately advanced cancer can’t usually be cured. But treatment might control it, help symptoms, and improve your quality of life for a while. The most common places for cervical cancer to spread is to the lymph nodes, liver, lungs and bones. Treatment for advanced cervical cancer depends on the size of the cancer and where it is in the body. Chemotherapy can be used to treat advanced cervical cancer. Some women may have an operation called pelvic exenteration for cervical cancer that has come back within the pelvis.

 

Request a sample and discover the recent advances in Advanced Cervical Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Advanced Cervical Cancer Treatment Landscape

 

Advanced Cervical Cancer Emerging Drugs Profile

 

Imfinzi (durvalumab): AstraZeneca

Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses. Imfinzi is the only approved immunotherapy in the curative-intent setting of unresectable, Stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed after chemoradiotherapy, and is the global standard of care in this setting based on the PACIFIC Phase III trial. Imfinzi is also approved in the US, EU, Japan, China and many other countries around the world for the treatment of extensive-stage small cell lung cancer based on the CASPIAN Phase III trial. As part of a broad development programme, Imfinzi is being tested as a single treatment and in combinations with other anti-cancer treatments for patients with small cell lung cancer, NSCLC, bladder cancer, several gastrointestinal cancers, ovarian cancer, endometrial cancer and other solid tumours. Currently, it is in Phase III stage of clinical trial evaluation to treat Locally Advanced Cervical Cancer. 

 

Dostarlimab: GlaxoSmithKline

Dostarlimab is a humanised PD-1 monoclonal antibody that binds with high affinity to the PD-1 receptor and blocks its interaction with the ligands PD-L1 and PD-L2. Currently, it is in Phase II stage of clinical trial evaluation to treat Locally Advanced Cervical Cancer. 

 

Andes 1537: Andes Biotechnologies

Andes-1537, a proprietary antisense oligonucleotide designed by Andes Biotechnology, is the Company’s most advanced investigational drug candidate and the first to enter a human clinical study. It targets a novel non-coding mitochondrial RNA (ncmtRNA) and has demonstrated antineoplastic activity in preclinical studies. Upon administration, Andes-1537 binds to a specific ncmtRNA, inducing cell cycle arrest and apoptosis of cancer cells. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Cervical Cancer.

 

Advanced Cervical Cancer Pipeline Therapeutics Assessment

There are approx. 70+ key companies which are developing the therapies for Advanced Cervical Cancer. The companies which have their Advanced Cervical Cancer drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.

 

For further information, refer to the detailed Advanced Cervical Cancer Unmet Needs, Advanced Cervical Cancer Market Drivers, and Market Barriers, click here for Advanced Cervical Cancer Ongoing Clinical Trial Analysis

 

Scope of the Advanced Cervical Cancer Pipeline Report

 

  • Coverage: Global

 

  • Advanced Cervical Cancer Companies: Akeso Biopharma, Hookipa Biotech GmbH, Biocad, Shanghai Henlius Biotech, Genexine, Inc., GlaxoSmithKline, EMD Serono, Zeria Pharmaceutical, Agenus Inc., Corregene Biotechnology Co., Ltd, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nykode Therapeutics, Instil Bio, Fujifilm Pharmaceuticals U.S.A., Inc., Nurix Therapeutics, Inc., Bristol-Myers Squibb, NETRIS Pharma, Suzhou BlueHorse Therapeutics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Xencor, Inc., Adlai Nortye Biopharma Co., Ltd., SOTIO, Astex Pharmaceuticals, Inc., Rubius Therapeutics, Seagen Inc., Kymab Limited, Incyte Corporation, Ocellaris Pharma, Inc., NGM Biopharmaceuticals, Inc., Nurix Therapeutics, Inc., Andes Biotechnologies, Arcus Biosciences, Inc., AstraZeneca, OncoC4, Inc., Turnstone Biologics, Corp., Nanobiotix, HiFiBiO Therapeutics, Corvus Pharmaceuticals, Inc., NGM Biopharmaceuticals, Inc., Prelude Therapeutics, Medicenna Therapeutics, Inc., Tarveda Therapeutics, Synthekine, RAPT Therapeutics, Inc., Shattuck Labs, Inc., BioAtla, Inc., Quadriga Biosciences, Inc., Klus Pharma Inc., Exelixis, Jiangsu HengRui Medicine Co., Ltd., Genor Biopharma Co., Ltd., Genentech, Qilu Pharmaceutical Co., Ltd., Lee’s Pharmaceutical Limited, Guangzhou Gloria Biosciences Co., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd., ISA Pharmaceuticals B.V., Agenus Inc., Cellid Co., Ltd., Advenchen Laboratories, LLC, TCRCure Biopharma Ltd., Iovance Biotherapeutics, Inc., MacroGenics, Transgene, Nanobiotix, Antengene Corporation, and others

 

  • Advanced Cervical Cancer Pipeline Therapies: AK104, HB-201, BCD-100, HLX10, GX-188E, TSR-042, M7824, Z-100, CRTE7A2-01, TQ-B3525, VB10.16, Bintrafusp alfa, ITIL-168, FF-10850, De-TIL-0255, BMS-986340, NP137, LM 103, SG001, AK112, XmAb20717, SO-C101, AN0025, ASTX660, RTX-321, SGN-ALPV, KY1044, SGN-B6A, INCB099318, OC-001, NGM707, NX-1607, Andes-1537, AB308, AZD8701, ONC-392, TBio-6517, NBTXR3, SEA-TGT, HFB200301,  CPI-006, NGM438, PRT1419, MDNA11, PEN-866, tucatinib, STK-012, FLX475, SL-279252, BA3071, QBS10072S, A166, XB002, TQB2450, SHR-1210, GB226, Atezolizumab, QL1604, ZKAB001, GLS-010, SHR-1701, ISA101b, SG001, AGEN1884, BVAC-C, AL3818, TC-E202 cells, LN-145, NP137, SO-C101, XmAb20717, MGD013, TG4001, QBS10072S, NBTXR3, ATG-008, and others.

 

  • Advanced Cervical Cancer Pipeline Segmentation: Phases, Product Type, Molecule Type, Mechanism of Action, Route of Administration

 

 

Dive deep into rich insights for drugs for Advanced Cervical Cancer Market Drivers and Advanced Cervical Cancer Market Barriers, click here @ Advanced Cervical Cancer Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Advanced Cervical Cancer Executive Summary
  3. Advanced Cervical Cancer: Overview
  4. Advanced Cervical Cancer Pipeline Therapeutics
  5. Advanced Cervical Cancer Therapeutic Assessment
  6. Advanced Cervical Cancer – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Advanced Cervical Cancer Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Durvalumab: AstraZeneca
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. Dostarlimab: GlaxoSmithKline
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. Andes 1537: Andes Biotechnologies
  17. Drug profiles in the detailed report…..
  18. Inactive Products
  19. Advanced Cervical Cancer Key Companies
  20. Advanced Cervical Cancer Key Products
  21. Advanced Cervical Cancer- Unmet Needs
  22. Advanced Cervical Cancer- Market Drivers and Barriers
  23. Advanced Cervical Cancer- Future Perspectives and Conclusion
  24. Advanced Cervical Cancer Analyst Views
  25. Advanced Cervical Cancer Key Companies
  26. Appendix

 

Got Queries? Find out the related information on Advanced Cervical Cancer Mergers and acquisitions, Advanced Cervical Cancer licensing activities @ Advanced Cervical Cancer Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services